Two Sigma Advisers’s Decoy Therapeutics DCOY Stock Holding History

Two Sigma Advisers’s Portfolio DCOY Stock Details DCOY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9	Closed	-$60K	–	2679
2022 Q3	$60K	Hold	9	–	–	﹤0.01%	2361
2022 Q2	$69K	Sell	9 -1	-10%	-$8.63K	﹤0.01%	2441
2022 Q1	$141K	Sell	10 -3	-23%	-$47.3K	﹤0.01%	2444
2021 Q4	$224K	Buy	13 +10	+333%	+$265K	﹤0.01%	2246
2021 Q3	$114K	Buy	+3	New	+$104K	﹤0.01%	2313

Other funds holding DCOY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Two Sigma Advisers's DCOY Position: Q4 2022 in Review

Two Sigma Advisers sold out of Decoy Therapeutics (DCOY) in Q4 2022, closing a stake of 9 shares — an estimated $60K sold.

Two Sigma Advisers first reported a position in DCOY in Q3 2021 and held it in 5 quarters. The position peaked at $224K in Q4 2021. 4 funds tracked by Wall St. Rank hold DCOY as of Q4 2022.

Two Sigma Advisers reported no remaining Decoy Therapeutics position as of Q4 2022 after selling out during the quarter.
Two Sigma Advisers sold 9 Decoy Therapeutics shares in Q4 2022, an estimated $60K.
Two Sigma Advisers first reported a position in Decoy Therapeutics in Q3 2021 and held it in 5 quarters.
Two Sigma Advisers's Decoy Therapeutics position peaked at $224K in Q4 2021.
4 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q4 2022.

Based on Two Sigma Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.